By touching $6.43 price per share a new yearly high was recored by XBiotech Inc. (NASDAQ:XBIT). Barchart.com reported it on Feb, 1. XBiotech Inc. (NASDAQ:XBIT) has $230.32 million MC. The valuation of NASDAQ:XBIT can change by $13.82M if our $6.82 PT is reached.
XBIT is touching $6.43 during the last trading session, after decreased 2.58%.XBiotech Inc. has volume of 89,745 shares. Since February 1, 2018 XBIT has declined 7.38% and is downtrending. The stock underperformed the S&P 500 by 7.38%.
For more XBiotech Inc. (NASDAQ:XBIT) news announced briefly go to: Seekingalpha.com, Globenewswire.com, Seekingalpha.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “Bounce/Lag Momentum – Winning Stocks In A Market Downturn – Seeking Alpha” announced on December 23, 2018, “XBiotech Announces Publication of Breakthrough Findings for Potential Role of Interleukin-1 alpha in Risk for Heart Attacks – GlobeNewswire” on August 27, 2018, “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” with a publish date: January 23, 2019, “XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease – Nasdaq” and the last “XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study – GlobeNewswire” with publication date: December 13, 2018.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases.The company has $230.32 million market cap. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.Currently it has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.